Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 5/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 3/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.34 |
| ▸ | CACNG8 | Q8WXS5 | 4/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26021814 | 0.80 | — | — | |
| SCHEMBL18189555 | 0.80 | TDP2 (0.42) | AHRCMA1GRM5TDP2MCL1 | |
| SCHEMBL20106901 | 0.80 | TDP2 (0.42) | AHRCMA1GRM5TDP2KCNH2 | |
| SCHEMBL25066324 | 0.77 | AHR (0.56) | AHRCMA1GRM5TDP2PGR | |
| SCHEMBL20094336 | 0.76 | TDP2 (0.34) | AHRCMA1GRM5TDP2PGR | |
| SCHEMBL5357730 | 0.74 | GRIA1 (0.49) | AHRCMA1GRM5TDP2PGR | |
| SCHEMBL4410702 | 0.74 | AHR (0.49) | AHRCMA1GRM5TDP2PGR | |
| SCHEMBL17292981 | 0.74 | AHR (0.49) | AHRCMA1GRM5TDP2PGR | |
| SCHEMBL25899903 | 0.74 | AHR (0.49) | AHRCMA1GRM5TDP2PGR | |
| SCHEMBL5365648 | 0.73 | AHR (0.49) | AHRCMA1GRM5TDP2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | AHR 3678/4885CMA1 299/4885GRM5 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.